---
schema_version: "secwatch.filing_event.v1"
accession: "0000078003-22-000068"
form_type: "8-K"
ticker: "PFE"
cik: "0000078003"
company_name: "PFIZER INC"
filed_at: "2022-05-03T23:59:59+00:00"
generated_at: "2026-06-26T01:44:12.364763+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Pfizer Q1 revenues $25.7B (+82%), EPS $1.62 adj.; reaffirms FY revenue $98-102B, adj. EPS $6.25-$6.45

## Summary
- Revenues $25.7B up 82% operationally; ex-COVID products +2% operational growth.
- Reported diluted EPS $1.37; Adjusted diluted EPS $1.62 (includes $0.05 negative from acquired IPR&D accounting change).
- Full-year revenue guidance reaffirmed $98-$102B; adjusted EPS guidance revised to $6.25-$6.45 from $6.35-$6.55.
- Comirnaty revenue guidance ~$32B; Paxlovid ~$22B; Chantix shipments remain paused globally due to impurity issue.
- Pfizer repurchased 39.1M shares for $2B in March at avg $51.10; remaining authorization $3.3B.

## SEC filing metadata
- accession: 0000078003-22-000068
- form_type: 8-K
- ticker: PFE
- cik: 0000078003
- company_name: PFIZER INC
- filed_at: 2022-05-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/78003/000007800322000068/0000078003-22-000068-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/78003/000007800322000068/pfe-20220503.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000078003-22-000068
- JSON: https://secwatch.observer/filing/0000078003-22-000068.json
- Plain text: https://secwatch.observer/filing/0000078003-22-000068.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.